Head and Neck Cancer Clinical Trials in Chicago, Illinois

6 studies are recruiting for head and neck cancer in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Illinois Cancer Center, Chicago, Illinois

   Locations

   90 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06172478 on ClinicalTrials.gov

2. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

   This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Chicago Medical Center, Chicago, Illinois

   Locations

   42 in total

   Run by

   Inhibrx Biosciences, Inc

   See if you can join NCT04198766 on ClinicalTrials.gov

3. A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment

   The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer who have detectable minimal-residual disease after definitive treatment. The ma…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Chicago, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT07179315 on ClinicalTrials.gov

4. A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

   By doing this study, the research team would like to learn if using a blood test that measures the amount of tumor DNA in blood can help guide how to use chemotherapy combined with immunotherapy for individuals with head and neck cancer. Using this blood test, the research team hopes to learn if in…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Chicago Comprehensive Cancer Center, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT05420948 on ClinicalTrials.gov

5. Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

   The purpose of this study is to evaluate the safety, tolerability and maximum tolerated dose of tislelizumab in combination with pamiparib plus chemoradiotherapy (chemotherapy and radiation) in individuals with recurrent head and neck cancer, which means that the person's cancer has come back after…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Chicago, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT05526924 on ClinicalTrials.gov

6. Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

   The purpose of this study is to assess the objective response rate following neoadjuvant therapy with volrustomig, paclitaxel, and carboplatin in previously untreated human papillomavirus (HPV)-negative locally advanced head and neck squamous cell carcinoma .

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Chicago, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT07065630 on ClinicalTrials.gov